Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Perjeta

(pertuzumab)

14 ML pertuzumab 30 MG/ML Injection [Perjeta]

Dosage & administration

* For intravenous infusion only. Do not administer as an intravenous push or bolus.
* HER2 testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency.
* The initial PERJETA dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion.
* MBC: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and docetaxel every 3 weeks.
* Neoadjuvant: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy preoperatively every 3 weeks for 3 to 6 cycles.
* Adjuvant: Administer PERJETA, trastuzumab or trastuzumab hyaluronidase-oysk, and chemotherapy postoperatively every 3 weeks for a total of 1 year (up to 18 cycles).

eficacy, safety & testing

Perjeta clinical details

Mechanism of Action

Clinical Trial: Neoadjuvant

Safety Profile: Neoadjuvant

Dosing: Neoadjuvant

Clinical Trial: Adjuvant

Efficacy: Adjuvant

Safety Profile: Adjuvant

Dosing: Adjuvant

Clinical Trial: Metastatic

Efficacy: Metastatic

Efficacy: Neoadjuvant

Safety Profile: Metastatic

Dosing: Metastatic

drug label

Perjeta prescribing information

Have more Perjeta questions?

Submit MSL Request

Learn More

Need to report a Perjeta issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Perjeta Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Combined Prescriber Service Form and Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Perjeta Financial assistance options

Co-pay savings program

commercial only

Combined Prescriber Service Form and Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Combined Prescriber Service Form and Patient Consent Form

Prescriber Service Form - Online Portal

Patient Consent Form - English

Patient Consent Form - Spanish

Genentech Patient Foundation Application Form - Prescriber Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Perjeta Patient education

Getting started on Perjeta

NOT PROVIDED BY BRANDInstructions For Use: Metastatic Breast Cancer

NOT PROVIDED BY BRANDInstructions For Use: Early Breast Cancer (Neoadjuvant)

NOT PROVIDED BY BRANDInstructions For Use: Early Breast Cancer (Adjuvant)